

January 17, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroze Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	---

Dear Sir/Madam,

Sub: CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO – Reg.,

Ref: Our letter dated July 4, 2023

CuraTeQ Biologics Pvt. Ltd., a wholly owned subsidiary of Aurobindo Pharma Ltd, today received from Subject Experts Committee (SEC) operating under the aegis of CDSCO (Central Drugs Standard Control Organization) a recommendation for grant of marketing authorization of biosimilar trastuzumab. Trastuzumab biosimilar, supplied in single dose glass vials containing 150 mg and 420 mg lyophilized powder for concentrate for solution for infusion, is a humanized monoclonal antibody for treating metastatic breast cancer and early breast cancer that is human epidermal growth factor receptor 2 positive. CuraTeQ was asked to submit Phase IV clinical trial protocol to CDSCO within three months of receiving the marketing authorization.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/ 2374 6833